Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01093326 · ClinicalTrials.gov registry record · Phase 2
Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis
A Phase 2 study, sponsored by Actelion.
- Completed
- Registry status
- Phase 2
- Development phase
- 353
- Enrollment target
NCT01093326 is a Phase 2 study that has completed, run by Actelion. The registered enrollment target is 353 participants.
The verdict
NCT01093326, a Phase 2 study, has completed, sponsored by Actelion.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 353 participants
- Enrollment target
Study Summary
This study is an extension to the study AC-058B201 and will investigate the long-term safety, tolerability and efficacy of ponesimod in patients with relapsing-remitting multiple sclerosis.
Interventions
- DRUG Ponesimod 10 mg
- DRUG Ponesimod 20 mg
- DRUG Ponesimod 40 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 353 participants |
| Start Date | 2010-05-12 |
| Est. Completion | 2023-09-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01093326
The ClinicalTrials.gov registry entry for NCT01093326 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 353 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actelion, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ponesimod 10 mg is the first listed.
NCT01093326 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01093326 about?
NCT01093326 is a clinical study titled "Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis". This study is an extension to the study AC-058B201 and will investigate the long-term safety, tolerability and efficacy of ponesimod in patients with relapsing-remitting multiple sclerosis.
What is the current status of trial NCT01093326?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 353 participants. The study started on 2010-05-12. Estimated completion is 2023-09-06.
What interventions are being tested in trial NCT01093326?
The interventions under investigation include: Ponesimod 10 mg (DRUG), Ponesimod 20 mg (DRUG), Ponesimod 40 mg (DRUG).
Who is sponsoring clinical trial NCT01093326?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.